Search:
Filter:
Sort:
Americans buying prescription medicines in Mexico are overlooking widespread drug counterfeiting in the country, and as AFPs popularize medical tourism to lower costs, what happens in Mexico’s drug supply chain is even more of a problem for Americans.
Prescription Drug Affordability Board Activity, April and May 2026 Activities Summary Maryland: In its April meeting, the Maryland PDAB set a UPL on Jardiance. In its May meeting, the board set a UPL on Ozempic. Virginia: Virginia’s governor vetoed the highly anticipated bills that would have established a PDAB in her state. Colorado: The PDAB provided notice of UPL rulemaking for…
The scheme, which produced counterfeit oxycodone, Adderall, and Xanax, is linked to over a dozen deaths, according to prosecutors.
Ozempic, the second drug that the state has set an upper payment limit on, will be capped at $274 for a 30-day supply.
Gilead Sciences has filed a complaint against Pain Relief Rx and other companies that it alleges sold diverted medicines on pharmacy to pharmacy marketplaces.
The ProRx warning letter signals increased FDA scrutiny of compounded weight loss product that are not intended to be compounded in the US.
Criminal counterfeiters are exploiting Americans’ demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide, while compounders, telehealth companies, and med spas strain and skirt public health measures to meet high demand.
An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper? On May 18, 2026, PSM sent a letter rebuking the Arkansas Democrat-Gazette for selling ad space to a Canadian online pharmacy last month. The advertisement, which promised to “save buyer’s up to 80% on their prescription drugs,” promotes the purchase of non-FDA-approved, foreign…
In a major settlement, Made-in-China.com will stop selling research chemicals to U.S. buyers following an investigation by Connecticut’s Attorney General.
The FDA proposed restricting three GLP-1 drugs from the 503B bulks list, which would prevent outsourcing facilities from compounding them from raw ingredients without a clear clinical need.